Skip to main content

Table 1 Antiproliferative effect of CLX and MMC, alone and in co-administration at 48 h, in bladder cancer cell lines

From: The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line

 

UMUC3

UMUC-3- CX

5637

5637 si-CX

TCC sup

J82

 

EC50(μM)

CLX

14.2 ± 0.7

16.3 ± 0.8

> 50

> 50

15.7 ± 0.50

11.6 ± 0.31

MMC

1.69 ± 0.09

13.0 ± 1.0

0.93 ± 0.04

0.62 ± 0.05

0.83 ± 0.07

0.64 ± 0.09

CLX 1 μM + MMC

1.54 ± 0.1

6 ± 0.3

1.46 ± 0.10

0.59 ± 0.03

0.74 ± 0.08

0.48 ± 0.03

CLX 5 μM + MMC

1.75± 0.07

5.7 ± 0.2

1.31± 0.06

0.47 ± 0.01

0.68 ± 0.04

1.04 ± 0.10

CLX 10 μM + MMC

1.9 ± 0.1

4 ± 0.18

1.68 ± 0.11

1.01 ± 0.20

1.08 ± 0.20

1.09 ± 0.10

  1. EC 50 = the concentration of a compound where 50% of its maximal effect is observed.
  2. The EC50 values were obtained from non-linear iterative curve fitting by Prism v.3.0, GraphPad software.
  3. Compounds were tested at escalating doses, starting from 0.1 μM to 50 μM. Results are expressed as EC50.